Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 7, 2016, Pages 1044-1055.e3

  Lu, Mei ^a,a   Li, Jia ^a   Zhang, Talan ^a   Rupp, Loralee B ^a   Trudeau, Sheri ^a   Holmberg, Scott D ^b   Moorman, Anne C ^b   Spradling, Philip R ^b   Teshale, Eyasu H ^b   Xu, Fujie ^b   Boscarino, Joseph A ^c   Schmidt, Mark A ^d   Vijayadeva, Vinutha ^e   Gordon, Stuart C ^a   Xing, Jim ^b   Tong, Cindy ^b   Nerenz, David R ^a   Lamerato, Lois ^a   Akkerman, Nonna ^a   Oja Tebbe, Nancy ^a   Daar, Zahra S ^c   Smith, Robert E ^c   Parker, John V ^e   Donald, Judy L ^d   Keast, Erin M ^d   more..

^a HENRY FORD HEALTH SYSTEM   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

CHeCS; Fibrosis progression; Growth curve analysis of trajectory; Outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; ANTIVIRUS AGENT;

ADULT; AGE; AMINOTRANSFERASE TO PLATELET RATIO INDEX; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE COURSE; ETHNIC DIFFERENCE; FEMALE; FIBROSIS 4 SCORE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NONHUMAN; REMISSION; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT FAILURE; TREATMENT RESPONSE; AGED; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SERUM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SERUM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; UNITED STATES;

EID: 84971642394     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.01.009     Document Type: Article

References (23)

1. D'Ambrosio R., Aghemo A., Rumi M.G., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012, 56:532-543.
2. George S.L., Bacon B.R., Brunt E.M., et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49:729-738.
3. Mallet V., Gilgenkrantz H., Serpaggi J., et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008, 149:399-403.
4. Pockros P.J., Hamzeh F.M., Martin P., et al. Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 2010, 52:1193-1200.
5. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
6. Pol S., Carnot F., Nalpas B., et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004, 35:107-112.
7. Shiratori Y., Imazeki F., Moriyama M., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517-524.
8. American Association for the Study of Liver Diseases IDSoA. Recommendations for testing, managing, and treating hepatitis C. 2014. Available from: . Accessed: January 13, 2015. http://www.hcvguidelines.org.
9. Li J., Gordon S.C., Rupp L.B., et al. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat 2014, 21:930-937.
10. Tamaki N., Kurosaki M., Tanaka K., et al. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat 2013, 20:72-76.
11. Butt A.A., Yan P., Lo Re V., et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015, 175:178-185.
12. Regression of liver stiffness after sustained HCV virological responses among HIV/HCV- coinfected patients. AIDS 2015, 29:1-10. Cohort TACH.
13. North C.S., Hong B.A., Adewuyi S.A., et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013, 35:122-128.
14. Moorman A.C., Gordon S.C., Rupp L.B., et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis 2013, 56:40-50.
15. Lu M., Rupp L.B., Moorman A.C., et al. Comparative effectiveness research of chronic hepatitis B and C cohort study (CHeCS): improving data collection and cohort identification. Dig Dis Sci 2014, 59:3053-3061.
16. Haseltine E.L., Penney M.S., George S., et al. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis. J Viral Hepat 2015, 22:701-707.
17. Bureau UC. Data and documentation for the American Community Survey. Available from: . http://www.census.gov/acs/www/data_documentation/documentation_main.
18. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
19. Austin P.C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011, 46:399-424.
20. Lu M., Lyden P.D., Brott T.G., et al. Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. J Neurosci Methods 2005, 143:209-216.
21. Steventon A., Grieve R., Sekhon J. A comparison of alternative strategies for choosing control populations in observational studies. Health Serv Outcomes Res Methodol 2015, 15:1-25.
22. Holmberg S.D., Lu M., Rupp L.B., et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013, 57:240-246.
23. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.